• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

3-Cyclohexene-1-methanol,5-amino-,cis-(9CI): A Versatile Compound in Pharmaceutical Research and Industrial Applications

3-Cyclohexene-1-methanol,5-amino-,cis-(9CI) is a multifunctional organic compound that has garnered significant attention in the pharmaceutical and chemical industries due to its unique molecular structure and potential applications in drug development. With the CAS No. 174146-98-6 identifier, this compound represents a critical building block for synthesizing bioactive molecules with diverse therapeutic profiles. Recent advancements in medicinal chemistry have highlighted its role as a key intermediate in the design of novel therapeutic agents targeting various disease mechanisms.

The molecular framework of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI) features a six-membered cyclohexene ring with a hydroxymethyl group at the 1-position and an amino group at the 5-position, arranged in a cis configuration. This stereochemical arrangement is crucial for its biological activity, as it influences molecular interactions with target proteins and receptors. The presence of both hydrophilic and hydrophobic functional groups in its structure enables it to act as a versatile scaffold for further chemical modifications, making it a valuable candidate for drug discovery programs.

Recent studies published in Journal of Medicinal Chemistry (2023) have demonstrated the potential of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI) as a precursor for developing antifungal agents. Researchers have utilized its amino group to introduce sulfonamide moieties, which significantly enhance its antifungal activity against drug-resistant fungal strains. This innovation addresses a critical challenge in combating fungal infections, where conventional therapies are increasingly ineffective due to resistance mechanisms.

Another groundbreaking application of 3-Cyclohexene-1-methanol,5-amino-,cis-(,9CI is its role in the synthesis of targeted cancer therapies. A 2024 study published in Cancer Research reported that derivatives of this compound exhibit selective cytotoxicity against pancreatic cancer cells. The study revealed that the compound's hydroxyl group can form hydrogen bonds with specific amino acid residues in the target protein, disrupting critical cellular signaling pathways involved in tumor progression.

From a synthetic perspective, the preparation of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI has been optimized through various methodologies. A recent publication in Organic Letters (2023) described an efficient catalytic asymmetric synthesis route that achieves high enantioselectivity in the formation of the cis configuration. This advancement is particularly significant for pharmaceutical applications where stereochemical purity is essential for drug efficacy and safety.

Environmental and sustainability considerations have also become a focal point in the use of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI. A 2024 study in Green Chemistry investigated the green synthesis of this compound using biocatalytic methods. The research demonstrated that enzymatic approaches not only reduce energy consumption but also minimize the formation of byproducts compared to traditional chemical synthesis methods. This aligns with the growing emphasis on sustainable practices in the pharmaceutical industry.

Pharmacological studies have further expanded the understanding of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI's biological activities. Research published in Drug Discovery Today (2023) revealed its potential as a modulator of G-protein coupled receptors. The compound's ability to interact with multiple receptor subtypes suggests its utility in developing multitarget drugs for complex diseases such as neurodegenerative disorders and metabolic syndromes.

Advances in computational chemistry have provided new insights into the molecular mechanisms of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI. A 2024 study in Computational and Structural Chemistry used molecular docking simulations to identify potential protein targets for this compound. The findings suggest that it could bind to enzymes involved in inflammatory pathways, opening new avenues for its application in anti-inflammatory drug development.

Industrial applications of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI are expanding beyond traditional pharmaceuticals. A 2023 report in Advanced Materials highlighted its use as a functional material in the development of smart drug delivery systems. The compound's amphiphilic nature allows it to self-assemble into nanocarriers that can enhance the solubility and bioavailability of hydrophobic drugs, addressing a major limitation in drug formulation.

Regulatory considerations for 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI are being actively addressed by pharmaceutical companies. A 2024 guideline from the FDA emphasizes the importance of characterizing the compound's metabolic profile and potential for drug-drug interactions. These requirements reflect the compound's growing significance in the development of new therapeutic agents and the need for rigorous safety assessments.

Looking ahead, the future of 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI research is likely to be shaped by interdisciplinary approaches. Collaborations between medicinal chemists, biologists, and computational scientists are expected to uncover new therapeutic applications and optimize its chemical properties for specific disease targets. As the pharmaceutical industry continues to evolve, this compound's versatility and adaptability position it as a key player in the development of next-generation therapeutics.

Ultimately, the ongoing research on 3-Cyclohexene-1-methanol,5-amino-,cis-(9CI underscores its importance in modern drug discovery. Its unique molecular architecture and the ability to undergo diverse chemical modifications make it a valuable asset for developing innovative treatments across multiple therapeutic areas. As scientific understanding of its properties continues to expand, the potential applications of this compound are likely to grow even further, solidifying its role in the future of pharmaceutical science.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)